Arthur Franken

Arthur Franken is a General Partner at Gilde Healthcare and is leading the firms’ investment activities in the (bio)pharmaceutical sector. He joined Gilde in 2001 and is member of the founding team. He is active in venture and growth capital investments in the (bio)pharmaceutical, medtech, diagnostics and digital health sectors. He led the investments in Breath Therapeutics (acquired by Zambon), Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche), Noema Pharma, ProQR Therapeutics (IPO on NASDAQ) and STAT-Dx (acquired by QIAGEN). He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext, acquired by Sanofi-Aventis), Axonics (IPO on NASDAQ), Calypso Biotech, CVRx, Eargo (IPO on NASDAQ), FIRE1, and uniQure (IPO on NASDAQ). He represents Gilde on the boards of Calypso Biotech, Levicept, Moximed and Noema Pharma and served as a board member for Breath Therapeutics, FlowCardia, MTM Laboratories, ProQR Therapeutics and STAT-Dx until the trade sales or IPO. Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a master’s degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.